BioSpace News Archive

Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.

Syntimmune has appointed Jean-Paul Kress as president and CEO.

The tax was strongly opposed by the $150 billion a year industry that produces everything from catheters to heart stents to artificial joints

Neogen announced today that its revenues for the second quarter of its 2018 fiscal year, which ended Nov. 30, increased 12% to $101,817,000, from the previous year’s second quarter revenues of $90,717,000.

The new 7600 square feet custom-built, state-of-the-art facility hosts Denovo’s biomarker discovery platform, US clinical team and serves as Denovo’s US headquarters.

Rayovac’s new PRO LINE Advanced combines long lasting power with an easy to use package.

The approval of Xiidra is supported by the largest development program globally to-date for an investigational-stage dry eye disease therapy, consisting of five clinical trials with more than 2,500 patients.

Foresee and Megapharm announced today that they have entered into an exclusive license and distribution agreement for the commercialisation in Israel and the Palestinian Authority of Foresee’s FP-001 program.

ReadCoor announced a grant from the Chan Zuckerberg Initiative (CZI) and DAF, an advised fund of Silicon Valley Community Foundation, to spatially map cortical cells using Fluorescent in situ Sequencing (FISSEQ) for the Human Cell Atlas.

Jan. 3, 2018 12:00 UTC Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH Namodenoson improves steatosis, inflammation and ballooning in pre-clinical studies A Phase II study of Namodenoson is enrolling NAFLD/NASH patients PETACH TIKVA, Israel--( BUSINESS WIRE )-- Can-Fite BioPharma Lt